We are live on ! Find out more
CC

Commodore Capital Portfolio holdings

AUM $1.73B
1-Year Est. Return 298.96%
This Fund
S&P 500
This Quarter Est. Return
+43.14%
1 Year Est. Return
+298.96%
3 Year Est. Return
+2,048.53%
5 Year Est. Return
+6,668.48%
10 Year Est. Return
–
AUM
$1.36B
AUM Growth
-$236M
Cap. Flow
-$42.9M
Cap. Flow %
-3.14%
Top 10 Hldgs %
69.81%
Holding
40
New
4
Increased
10
Reduced
8
Closed
9

Top Buys

Rank Stock Value
1
PCVX icon
Vaxcyte
PCVX
+$70M
2
NUVL
Nuvalent
NUVL
+$63.7M
3
NRIX icon
Nurix Therapeutics
NRIX
+$30.9M
4
SRRK icon
Scholar Rock
SRRK
+$30.9M
5
MRUS
Merus
MRUS
+$25.2M

Top Sells

Rank Stock Value
1
CLDX icon
Celldex Therapeutics
CLDX
+$55M
2
CATX icon
Perspective Therapeutics
CATX
+$44.7M
3
KURA icon
Kura Oncology
KURA
+$35.2M
4
RYTM icon
Rhythm Pharmaceuticals
RYTM
+$34.1M
5
ARVN icon
Arvinas
ARVN
+$29.6M

Sector Composition

Rank Sector Weight
1 Healthcare 99.44%
2 Financials 0.56%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
MRUS
1
DELISTED
Merus
MRUS
$163M 11.94%
3,874,182
+524,182
+16% +$25.2M
PCVX icon
2
Vaxcyte
PCVX
$7.89B
$133M 9.75%
1,625,000
+705,000
+77% +$70M
NUVL
3
DELISTED
Nuvalent
NUVL
$127M 9.3%
1,621,600
+681,600
+73% +$63.7M
XENE icon
4
Xenon Pharmaceuticals
XENE
$6.32B
$107M 7.87%
2,740,000
+40,000
+1% +$1.65M
ELVN icon
5
Enliven Therapeutics
ELVN
$3.78B
$94.6M 6.93%
4,205,000
+105,000
+3% +$2.72M
VERA icon
6
Vera Therapeutics
VERA
$2.54B
$82.8M 6.07%
1,958,600
-516,400
-21% -$22.9M
SLNO
7
DELISTED
Soleno Therapeutics
SLNO
$68.5M 5.02%
1,525,000
+265,000
+21% +$13.7M
ALKS icon
8
Alkermes
ALKS
$8.82B
$66.1M 4.85%
2,300,000
-600,000
-21% -$17.2M
NRIX icon
9
Nurix Therapeutics
NRIX
$2.43B
$56.5M 4.14%
3,000,000
+1,350,000
+82% +$30.9M
COGT icon
10
Cogent Biosciences
COGT
$6.79B
$53.7M 3.93%
6,881,629
-658,301
-9% -$6.56M
SYRE icon
11
Spyre Therapeutics
SYRE
$8.87B
$46.3M 3.39%
1,988,084
– –
VRDN icon
12
Viridian Therapeutics
VRDN
$2.13B
$46M 3.37%
2,400,000
-150,124
-6% -$3.26M
SRRK icon
13
Scholar Rock
SRRK
$5.71B
$41.1M 3.01%
+950,000
New +$30.9M
CNTA
14
DELISTED
Centessa Pharmaceuticals
CNTA
$37.2M 2.72%
2,218,425
+868,425
+64% +$14.4M
PHVS icon
15
Pharvaris
PHVS
$2.39B
$36.6M 2.69%
1,911,433
– –
DFTX
16
Definium Therapeutics
DFTX
$5.73B
$30M 2.2%
4,308,425
-3,691,575
-46% -$25.4M
ORKA
17
Oruka Therapeutics
ORKA
$5.56B
$27.5M 2.02%
1,419,714
+50,000
+4% +$1.22M
CRDF icon
18
Cardiff Oncology
CRDF
$64.3M
$23.4M 1.71%
+5,384,616
New +$16.8M
IKT icon
19
Inhibikase Therapeutics
IKT
$366M
$19.3M 1.41%
+5,925,000
New +$14.8M
NGNE icon
20
Neurogene
NGNE
$696M
$18.3M 1.34%
800,000
+600,000
+300% +$22.3M
DRUG
21
Bright Minds Biosciences
DRUG
$700M
$18M 1.32%
+500,000
New +$17.6M
ORIC icon
22
Oric Pharmaceuticals
ORIC
$1.25B
$16.1M 1.18%
2,000,000
– –
APGE icon
23
Apogee Therapeutics
APGE
$10.2B
$13.1M 0.96%
290,000
– –
ABVX
24
Abivax
ABVX
$11B
$9.4M 0.69%
1,284,110
– –
PCSC
25
DELISTED
Perceptive Capital Solutions
PCSC
$7.63M 0.56%
750,000
– –
1
2

Similar funds

RIA
Regal Investment Advisors Kentwood, Michigan $1.73B AUM 17.74% 1-Year Est. Return
PAIM
Punch & Associates Investment Management Edina, Minnesota $1.73B AUM 27.65% 1-Year Est. Return
MCWS
McKinley Carter Wealth Services Wheeling, West Virginia $1.73B AUM 17.28% 1-Year Est. Return
VCA
Verdence Capital Advisors Hunt Valley, Maryland $1.72B AUM 24.88% 1-Year Est. Return
ESBC
E.S. Barr & Co Lexington, Kentucky $1.72B AUM 12.69% 1-Year Est. Return
MSR
Main Street Research Lakeville, Connecticut $1.72B AUM 48.78% 1-Year Est. Return
WJA
Willis Johnson & Associates Houston, Texas $1.72B AUM 16.93% 1-Year Est. Return
OMC
Oasis Management Company Grand Cayman, Cayman Islands $1.72B AUM 32.1% 1-Year Est. Return

Commodore Capital's Q4 2024 Portfolio in Review

As of Q4 2024, Commodore Capital held 40 positions worth $1.36B, down 15% from $1.6B the previous quarter. Its ten largest holdings account for 70% of the portfolio.

Commodore Capital withdrew a net $42.9M in Q4 2024, closing 9 positions and reducing 8 holdings. Its most notable exit was Celldex Therapeutics, an estimated $55M position sold in full.

By sector, the portfolio is most concentrated in Healthcare at 99% of assets, down from 100% a quarter earlier, followed by Financials.

Against the trend, Commodore Capital opened a new position in Scholar Rock worth $41.1M.

  • Commodore Capital's largest Q4 2024 buy was Scholar Rock: 950,000 shares worth $41.1M.
  • Commodore Capital added most to Vaxcyte in Q4 2024, an estimated $70M increase.
  • Commodore Capital's biggest Q4 2024 reduction was Definium Therapeutics, cutting an estimated $25.4M.
  • Commodore Capital fully exited Celldex Therapeutics in Q4 2024, selling an estimated $55M.
  • Commodore Capital's ten largest holdings make up 70% of its $1.36B portfolio in Q4 2024.
  • Commodore Capital opened 4 new positions and closed 9 in Q4 2024.
  • Commodore Capital's portfolio value fell 15% quarter-over-quarter to $1.36B.

Based on Commodore Capital's 13F filing for Q4 2024, filed 14 Feb 2025.